Multidrug and carbapenem-resistant Acinetobacter baumannii infections: Factors associated with mortality

被引:26
|
作者
Hernandez-Torres, Alicia
Garcia-Vazquez, Elisa [1 ]
Gomez, Joaquin [1 ]
Canteras, Manuel [2 ]
Ruiz, Joaquin
Yaguee, Genoveva
机构
[1] Univ Murcia, Dept Internal Med, Fac Med, Murcia, Spain
[2] Univ Murcia, Dept Biostat, Fac Med, Murcia, Spain
来源
MEDICINA CLINICA | 2012年 / 138卷 / 15期
关键词
Acinetobacter baumannii; Multidrug resistant; Infection; Mortality; Treatment; NOSOCOMIAL INFECTIONS; CLINICAL-FEATURES; COLISTIN; BACTEREMIA; RIFAMPICIN; EPIDEMIOLOGY; COMBINATION; TIGECYCLINE; MONOTHERAPY; IMIPENEM;
D O I
10.1016/j.medcli.2011.06.024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objective: To analyse factors related to mortality and influence of antibiotic treatment on outcome in patients with nosocomial infection due to multidrug and carbapenem-resistant Acinetobacter baumannii (MDR-C AB). Patients and methods: Observational and prospective study of a cohort of adult patients with MDR-C AB infection. Data collection from clinical records was done according to a standard protocol (January 2007 through June 2008). Patients with MDR-C AB infection were identified by review of results of microbiology cultures from the hospital microbiology laboratory. Epidemiological and clinical variables and predictors of mortality were analysed. Results: 24 out of 101 cases were considered colonizations and 77 infections (27 bacteraemia); global mortality in infected patients was 49% (18 cases with bacteraemia and 20 with no bacteraemia). In the multivariate analysis, including the 77 cases of infection, the prognosis factors associated with mortality were age (OR 1.09; 95% Cl 1.02-1.2), McCabe 1 (OR 33.98; 95% Cl 4.33-266.85), bacteraemia (OR 9.89; 95% Cl 1.13-86.13), inadequate empiric treatment (OR 16.7; 95% Cl 2.15-129.79), and inadequate definitive treatment (OR 26.29; 95% Cl 1.45-478.19). In the multivariate analysis including the 57 cases of infection with adequate definitive treatment, the prognosis factors associated with mortality were McCabe 1 (OR 24.08:95% Cl 3.67-157.96) and monotherapy versus combined treatment (OR 7.11; 95% Cl 1.63-30.99). Conclusions: Our cohort of patients with MDR-C AB infection is characterised by a very high mortality (49%); the severity of patients and inadequate treatment or monotherapy are statistically associated with mortality. 2011 (C) Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:650 / 655
页数:6
相关论文
共 50 条
  • [31] High prevalence of carbapenem-resistant Acinetobacter baumannii associated respiratory tract infections in Pakistani hospitals
    Khalid, Fizza
    Saleem, Sidrah
    Ahmad, Irfan
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2020, 70 (09) : 1630 - 1632
  • [32] Associations between Carbapenem Use, Carbapenem-Resistant Pseudomonas aeruginosa, and Carbapenem-Resistant Acinetobacter baumannii
    Apisarnthanarak, Anucha
    Jitpokasem, Sumana
    Mundy, Linda M.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2013, 34 (11): : 1235 - 1237
  • [33] Treatment Options for Carbapenem-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections
    Viehman, J. Alexander
    Hong Nguyen, M.
    Doi, Yohei
    DRUGS, 2014, 74 (12) : 1315 - 1333
  • [34] Risk factors for infection after carbapenem-resistant Acinetobacter baumannii colonization
    Peghin, Maddalena
    Givone, Filippo
    de Martino, Maria
    Ali, Raja Waqar
    Graziano, Elena
    Isola, Miriam
    Grossi, Paolo Antonio
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2024, 43 (11) : 2191 - 2199
  • [35] Molecular Mechanisms Associated with Nosocomial Carbapenem-resistant Acinetobacter baumannii in Mexico
    Dolores Alcantar-Curiel, Maria
    Francisco Garcia-Torres, Luis
    Ines Gonzalez-Chavez, Maria
    Morfin-Otero, Rayo
    Gayosso-Vazquez, Catalina
    Dolores Jarillo-Quijada, Ma.
    Luis Fernandez-Vazquez, Jose
    Giono-Cerezo, Silvia
    Rodriguez-Noriega, Eduardo
    Ignacio Santos-Preciado, Jose
    ARCHIVES OF MEDICAL RESEARCH, 2014, 45 (07) : 553 - 560
  • [36] Sulbactam and Durlobactam Combination as a Newer Antibiotic for Carbapenem-Resistant Acinetobacter baumannii Infections
    Nyamagoud, Sanatkumar Bharamu
    Swamy, Agadi Hiremath Viswanatha
    Abhishek, B. J.
    Varghese, Leena Elizabeth
    Bhoomika, S. K.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2024, 14 (02) : 289 - 298
  • [37] Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study
    Vivo, Amanda
    Fitzpatrick, Margaret A.
    Suda, Katie J.
    Jones, Makoto M.
    Perencevich, Eli N.
    Rubin, Michael A.
    Ramanathan, Swetha
    Wilson, Geneva M.
    Evans, Martin E.
    Evans, Charlesnika T.
    BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [38] Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study
    Amanda Vivo
    Margaret A. Fitzpatrick
    Katie J. Suda
    Makoto M. Jones
    Eli N. Perencevich
    Michael A. Rubin
    Swetha Ramanathan
    Geneva M. Wilson
    Martin E. Evans
    Charlesnika T. Evans
    BMC Infectious Diseases, 22
  • [39] Intravenous Fosfomycin: The Underdog Player in the Treatment of Carbapenem-resistant Acinetobacter baumannii Infections
    Guastalegname, Maurizio
    Trecarichi, Enrico Maria
    Russo, Alessandro
    CLINICAL INFECTIOUS DISEASES, 2023, 77 (12) : 1736 - 1737
  • [40] Clinical characterization of patients with carbapenem-resistant versus carbapenemsusceptible Acinetobacter baumannii infections
    Tyagi, I.
    Koirala, J.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E44 - E44